On August 19 China Daily published a profile of SinoUnited Health, marking ten years since the practice opened. It opens with a patient who traveled from New Zealand to Shanghai for CAR T-cell therapy, and closes on where the organization is heading.
The patient is Dale, whose own account is already on this site. He was diagnosed in 2023 with stage 4 diffuse large B-cell lymphoma, chemotherapy did not work for him, and he came to Shanghai in 2024 for CAR T-cell therapy at SinoUnited Health. Fourteen months after his infusion he returned to speak at SinoUnited Health’s International Medical Forum.
“SinoUnited Health rekindles hope for patients worldwide”— China Daily, August 19, 2026
What kind of piece this is
It is worth being plain about this, because it changes how much weight the piece should carry for you. This is a profile published in China Daily’s business section to mark SinoUnited Health’s tenth year. It carries no reporter’s byline, and the people quoted in it — Dr. Kathy Shi, founder and CEO of SinoUnited Health, and the patient — were introduced by the hospital. It is not an independent investigation, and we do not present it as one.
SinoUnited Health did not pay for the article. That is worth saying, because a corporate profile in a business section is the shape advertising often takes. But unpaid is not the same as independent, and the distinction above still holds.
What it is useful for is context: it sets out why patients from outside China have begun traveling to Shanghai, and it places the CAR T-cell therapy program inside the wider hospital it belongs to.
What the piece says about traveling to China
On the wider picture, the article describes Shanghai emerging as one of China’s centers for advanced medical care, and attributes the arrival of international patients to a combination of medical technology, multidisciplinary care and cost. It also describes CAR T-cell therapy as reprogramming a patient’s own T-cells — the mechanism is set out at greater length on our therapies pages.
Where SinoUnited Health stands
CAR T-cell therapy at SinoUnited Health is not offered through a clinical trial. Every therapy described on this site is one the National Medical Products Administration has approved for commercial use in China, and each therapy page sets out the indication wording under which that approval was granted. An approval in China is not a statement about availability or funding anywhere else.
On cost
The article observes that treatment in China costs less than in many Western countries. It prints no figures. This site keeps every figure in one place, on the costs page, alongside what the package covers and what it does not.
What is not repeated here
The article describes how Dale’s treatment turned out, in his words and in the writer’s. That result is not restated on this page. This site does not publish response, remission or survival figures — not its own, not from published research, and not from press coverage. Nor does it publish one person’s result as though it forecast anyone else’s.
Dale has told his own story here, in his own words and at his own length, and it remains the better place to read it. His account and five others are on the patient stories page. They are personal accounts, and not a prediction of results for anyone else.
The article also covers parts of SinoUnited Health that have nothing to do with CAR T-cell therapy — a second patient, the hospital’s history and size, its other specialties and its plans. Those are outside what this site sets out to cover, and we have left them where they were published.
Read the article at chinadaily.com.cn Free to read. No subscription required.
